DECEMBER 2008
Meabco's medical advisor has advised that the applications and
protocols for clinical trials complementary to the phase I/II(toxicity) trials already performed in Denmark are being filed.
AUGUST 2008
The US Patent and Trademark Office
grants patent on the use of BP-C1 as an anti cancer agent.
AUGUST 2008
Meabco A/S has received approval
(by the participating centre)
to initiate a placebo-controlled randomized Phase II/III trial for
BP-C1 in breast cancer patients.
JUNE 2008
Meabco A/S
initiates collaboration with the Department of Tumor
Endocrinology, Institute of Cancer Biology, Danish Cancer Society to study
further the mechanism of action of BP-C1.
MARCH 2008
Meabco A/S
announces promising results from an open-label Phase I/II trials for
BP-C1 in breast cancer.
JANUARY 2008
Meabco A/S
secures yet another round of financing, enabling the company to
complete Phase II/III trials for BP-C1 in breast cancer.
DECEMBER 2007
The European
Patent office grants patent on the use of BP-C1 as an anti cancer
agent.